Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - Integer also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, a decline of over 32%, from $109.11 per share on October 22, 2025, to $73.89 per share on October 23, 2025 [6].

Core Insights - Siemens Healthineers reported a strong start to fiscal 2026, confirming its full-year outlook despite facing significant headwinds in diagnostics due to market changes in China [4][13] Imaging Segment - Imaging adjusted EBIT margin was 21.6%, reflecting strong operational margin expansion, with external pressures from tariffs and foreign exchange impacting margins by approximately 200 basis points [1] - Revenue in the imaging segment grew by 5.7% in Q1, driven by photon-counting CT and radiopharmaceuticals, with a comparability change due to an acquisition from Novartis [2] - The combined growth for imaging and precision therapy was around 6%, with a decent equipment book-to-bill ratio of 1.12 [3][5] Diagnostics Segment - Diagnostics revenue fell by about 3% due to volume-based procurement and reimbursement cuts in China, which saw a decline of approximately 5% for the group [5][7] - Outside of China, diagnostics revenues remained stable, with the Americas diagnostic business showing operational growth, particularly from the Atellica franchise, which grew roughly 20% in Q1 [8][10] - Management expects Q2 diagnostics performance to be below the annual growth range due to ongoing challenges in China [14] Financial Performance - The company achieved a group revenue growth of 3.8%, with strong performance in imaging and precision therapy offsetting the decline in diagnostics [10] - Adjusted EPS declined by 3% year-over-year, but excluding the impacts of tariffs and foreign exchange, adjusted EPS would have increased by about 17% [11] - The adjusted EBIT margin for the group was 15%, remaining flat year-over-year, but operationally expanded by 200 basis points when excluding external pressures [10] Tariffs and Foreign Exchange - Tariffs and foreign exchange are expected to be ongoing headwinds throughout fiscal 2026, with quantified impacts of approximately $0.04 from foreign exchange and $0.06 from tariffs in Q1 [12][18] - The company anticipates fully mitigating the impact of tariffs over the next three years, describing them as a temporary drag on margins [12][18] Outlook - Siemens Healthineers confirmed its fiscal 2026 outlook for revenue growth and adjusted EPS, supported by strong performance in imaging and precision therapy [13] - For Q2, the company expects group revenue growth to be below the fiscal 2026 range of 5% to 6%, primarily due to diagnostics challenges in China [14][15]

Core Insights - Siemens Healthineers reported first-quarter operating profit that exceeded market expectations, driven by strong margin performance in its core imaging and cancer-care units [1] - The company experienced a decline in other areas, but the robust performance in its primary segments helped mitigate the overall impact [1] Financial Performance - The operating profit for the first quarter was notably higher than analysts' forecasts, indicating a positive trend in financial health [1] - The strong margins in imaging and cancer-care units suggest effective cost management and operational efficiency [1]

La Neve emphasized that cost actions are intended to support longer-term strategies, including efforts to strengthen commercial execution and create a more predictable, higher-margin growth model. He said Accuray has tightened weekly and monthly financial and operating reviews around orders, revenue, margins, service performance, and cash, with an emphasis on faster corrective actions and greater accountability.Management reiterated that the plan targets an approximately $25 million improvement in annualize ...

Core Viewpoint - Align Technology reported quarterly results that exceeded Wall Street expectations and forecasted first-quarter revenue in line with estimates, driven by strong demand for its dental aligners [1] Financial Performance - The company achieved quarterly results above Wall Street expectations, indicating robust financial health and operational efficiency [1] - The forecast for first-quarter revenue aligns with market estimates, suggesting stability in future earnings [1] Market Demand - Strong demand for dental aligners has been a significant driver of the company's performance, highlighting a positive trend in consumer preferences towards orthodontic solutions [1]

New York, New York--(Newsfile Corp. - February 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024 and October 22, 2025, both dates inclusive (the "Class Period"), of the important February 9, 2026 lead plaintiff deadline.SO WHAT: If you purchased Integer common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Picard Medical, Inc. (PMI) securities between September 2, 2025, and October 31, 2025, due to allegations of a fraudulent stock promotion scheme [1][2]. Group 1: Allegations Against Picard Medical - The complaint alleges that Picard Medical was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [2]. - It is claimed that insiders and/or affiliates utilized offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures reportedly failed to mention the false rumors and artificial trading activity that influenced the stock price [2]. Group 2: Stock Price Impact - On October 24, 2025, Picard's stock price experienced a significant crash of 70%, dropping to $3.99 per share, and has since continued to decline to approximately $2.00 per share [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by April 3, 2026, although participation is not required to be eligible for recovery [4]. - Individuals can choose to remain absent class members if they do not wish to take action [4]. Group 4: Robbins LLP Overview - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Financial Data and Key Metrics Changes - Q4 revenues reached a record $1.048 billion, up 5.3% year-over-year and 5.2% sequentially, while full year 2025 revenues were $4 billion, up 1% year-over-year [5][33] - Non-GAAP gross margin for Q4 was 72%, up 1.6 points sequentially and 1.2 points year-over-year, while GAAP gross margin was 65.3%, up 1.1 points sequentially but down 4.8 points year-over-year [40][42] - Q4 operating income was $155.3 million, resulting in an operating margin of 14.8%, up approximately 5.2 points sequentially and 0.3 points year-over-year [46] Business Line Data and Key Metrics Changes - Systems and services revenues were $790 million, up 2.7% year-over-year, while clear aligner revenues for fiscal 2025 were $3.2 billion, up 0.5% year-over-year with record clear aligner volumes of 2.6 million cases [6][7] - Q4 clear aligner revenues were $838 million, up 5.5% year-over-year and 4% sequentially, with a record volume of 677,000 cases, up 7.7% year-over-year [7][8] - Q4 systems and services revenues were $209.4 million, up 10.3% sequentially and 4.2% year-over-year, driven by higher scanner system sales [37][38] Market Data and Key Metrics Changes - Clear aligner volume growth in Q4 was driven by strength in EMEA, Latin America, and APAC, with stability in North America [8][15] - In EMEA, DSO performance showed double-digit growth year-over-year, while in Latin America, clear aligner volumes grew double digits, achieving record quarterly shipments [14][15] - In APAC, clear aligner volumes also grew double digits year-over-year, with significant contributions from China, India, and Korea [19] Company Strategy and Development Direction - The company aims to expand international adoption, increase orthodontic utilization, and strengthen consumer demand conversion through localized marketing [63][68] - The focus on DSOs as a strategic growth channel is emphasized, with partnerships driving digital dentistry adoption [10][12] - Investments in innovation, including AI-driven treatment planning and direct fabrication capabilities, are prioritized to enhance margins and operational efficiency [66][68] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the macro environment, highlighting the importance of disciplined execution across regions and channels [67] - The company expects Q1 2026 worldwide revenues to be in the range of $1.01 billion to $1.03 billion, reflecting a year-over-year growth of 3%-5% [58] - For fiscal 2026, the company anticipates revenue growth of 3%-4% year-over-year, with clear aligner volume growth expected to be in the mid-single digits [60] Other Important Information - Cash and cash equivalents as of December 31, 2025, were $1.0949 billion, with $831.2 million remaining available for stock repurchases under the program [53][55] - The company repurchased approximately 0.7 million shares in Q4 2025 at an average price of $142.87 [54] Q&A Session Summary Question: Can you parse apart the improved volume performance? - Management noted stability in markets and effective execution, particularly with DSOs driving growth [72] Question: What are the assumptions for 2026 guidance regarding end markets? - Management expects markets to behave consistently with recent trends, focusing on active conversion strategies [83] Question: Can you discuss the growth of DSOs and their adoption curve? - Management indicated that DSOs are expanding and that there are still growth opportunities in this segment [86] Question: What is driving the improvement in the adult business? - Factors include DSO growth, financial credit availability, and effective patient conversion strategies [92] Question: How do you view ASPs for 2026? - Management expects ASPs to decline by 1%-2% year-over-year due to country and product mix [101]

Financial Data and Key Metrics Changes - Q4 2025 revenues reached a record $1.048 billion, up 5.3% year-over-year and 5.2% sequentially [3][19] - Full year 2025 total revenues were $4 billion, up 1% year-over-year [3] - Non-GAAP operating margin for Q4 was 22.7%, the highest since 2021 [4] - Q4 overall gross margin was 65.3%, up 1.1 points sequentially but down 4.8 points year-over-year [23][24] Business Line Data and Key Metrics Changes - Systems and services revenues were $790 million, up 2.7% year-over-year [4] - Clear aligner revenues for Q4 were $838 million, up 5.5% year-over-year and up 4% sequentially [4][20] - Fiscal 2025 clear aligner revenues were $3.2 billion, up 0.5% year-over-year with record volumes of 2.6 million cases [4] Market Data and Key Metrics Changes - Q4 clear aligner volume was a record 677,000 cases, up 7.7% year-over-year [5] - Strong growth in EMEA, Latin America, and APAC, with stability in North America [5] - In North America, clear aligner volumes were up year-over-year, with double-digit growth in Latin America [9] Company Strategy and Development Direction - Focus on expanding international adoption and increasing orthodontic utilization, particularly among teens and kids [36][38] - Strengthening partnerships with dental service organizations (DSOs) to drive digital dentistry adoption [6][9] - Continued investment in innovation, including AI-driven treatment planning and direct fabrication capabilities [38] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2026, emphasizing the importance of disciplined execution across regions and channels [36][39] - The macro environment remains dynamic, but the company is encouraged by progress in key customer segments [36] - Management highlighted the need for sustained momentum in North America and improving conversion rates [38] Other Important Information - Cash and cash equivalents as of December 31, 2025, were $1.0949 billion, up $90.3 million sequentially [30] - The company repurchased approximately 0.7 million shares at an average price of $142.87 during Q4 2025 [31] Q&A Session Summary Question: Improved volume performance and its drivers - Management noted stability in markets and effective execution, particularly with DSOs driving growth [42][43] Question: Guidance assumptions for 2026 - Management expects markets to behave similarly to the second half of 2025, focusing on active conversion strategies [51][52] Question: DSO adoption curve and growth potential - Management indicated continued DSO penetration and growth opportunities, with many DSOs expanding globally [53][55] Question: Adult business performance and drivers - Management attributed improved adult business performance to DSOs, financial credit options, and effective patient conversion strategies [60][61] Question: North American retail business stability - Management reported improved stability in the North American retail business, aided by DSOs and a broader product portfolio [63][64] Question: ASP expectations for 2026 - Management anticipates ASPs to decline by 1%-2% year-over-year due to product and country mix [67][70] Question: Tax receipts and stimulus impact - Management did not plan around potential tax receipts but acknowledged them as possible upside [72]

Q2'FY26 Earnings Call Supplemental Presentation February 4, 2026 Forward-looking Statements This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements i ...